HEMATOPOIETIC STEM CELL RENEWAL FACTOR

血细胞是通过一个称为造血的过程产生的。 的 源 造血干细胞（HSC）是造血干细胞的一种。 为 干 细胞产生的细胞成为定型血细胞，他们 必须 更新或复制。 血细胞生成受一组 因素 称为造血生长因子。 有一些因素 影响 细胞在发育早期、中期和晚期， 发展 这些因子通过细胞表面受体起作用， 调节这些细胞的生长和发育。 当有 需要 对于血细胞，这些因子被上调。 的因素 反过来 刺激特定血细胞类型的产生增加 必需的. 与其他的调节类似 造血 干细胞的再生似乎是在 的 调节一种叫做干细胞更新因子的生长因子 （SCRF）。 在第一阶段，开发了新的研究工具， 重要 与一个学术实验室建立了合作关系。 这些 发展将使分离cDNA编码的目标， SCRF至 在第二阶段完成。 此外，生产过程和 将制定纯化方案，并进行动物研究。 执行。 SCRF将用于治疗癌症 患者 增加血细胞生产，作为采集前的预处理 的 外周血造血干细胞 移植，以及作为在培养物中扩增干细胞的试剂 为 干细胞移植和基因治疗。

Blood cells are produced by a process known as hematopoiesis. The source of all blood cells is the hematopoietic stem cell (HSC). As the stem cell gives rise to cells which become committed blood cells, they must be renewed or duplicated. Hematopoiesis is regulated by a group of factors known as hematopoietic growth factors. There are factors which affect cells early in development, midway through development, and late in development. These factors act through cell surface receptors to regulate the growth and development of these cells. When there is a need for blood cells, these factors are up-regulated. The factors in turn stimulate an increase of production of the specific blood cell type required. With analogy to the regulation of the other hematopoietic cells development, the renewal of stem cells appears to be under the regulation of a growth factor called stem cell renewal factor (SCRF). During Phase I, novel research tools were developed and an important collaboration was established with an academic laboratory. These developments will enable the goal of isolating the cDNA encoding SCRF to be accomplished in Phase II. In addition, production processes and purification scheme will be developed and animal studies will be performed. SCRF will be useful for the treatment of cancer patients to increase production of blood cell, as a pretreatment to collection of peripheral hematopoietic stem cells for autologous stem cell transplantation, and as an agent to amplify stem cells in culture for stem cell transplantation and gene therapy.